Clinical Trials
67 trialsNovel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
University of Florida
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
LauT1
Centre Hospitalier Universitaire Vaudois
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
A Study of CRD3874-SI in People With Solid Tumors
Memorial Sloan Kettering Cancer Center
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
M.D. Anderson Cancer Center
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
Iovance Biotherapeutics, Inc.
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
Guangzhou FineImmune Biotechnology Co., LTD.
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
Baylor College of Medicine
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Eli Lilly and Company
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Y-mAbs Therapeutics
DUET-3
Xencor, Inc.
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Gene Surgery LLC
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Institutes of Health Clinical Center (CC)
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Pfizer
A Study of PRT1419 in Patients With Advanced Solid Tumors
Prelude Therapeutics
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
GEN602
Genzada Pharmaceuticals USA, Inc.
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Ludwig Institute for Cancer Research
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Pfizer
A Safety Study of SGN-CD47M in Patients With Solid Tumors
Seagen Inc.
Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
National Institutes of Health Clinical Center (CC)
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
University of Chicago
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
National Institutes of Health Clinical Center (CC)
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
National Institutes of Health Clinical Center (CC)
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
The Cleveland Clinic
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)